Velcade Rebate Scheme In U.K. Sets Up Broader Cost-Effectiveness Review

An innovative cost-sharing arrangement in which Johnson & Johnson will rebate the cost of the cancer drug Velcade (bortezomib) when patients have a minimal response will be implemented in the U.K. by early 2008